Herpes Zoster Market to Reach USD 7.94 Billion by 2034

The Global Herpes Zoster Market is witnessing steady expansion as vaccination campaigns, improved antiviral therapies, and awareness of shingles prevention continue to grow worldwide. According to Exactitude Consultancy, the market, valued at USD 5.02 billion in 2024, is projected to reach USD 7.94 billion by 2034, registering a CAGR of 4.6 % during 2025-2034.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/49177

Rising incidence among the elderly population, coupled with ongoing immunization initiatives using advanced recombinant vaccines, are key drivers shaping this market's strong outlook.

Key Takeaways
• Market Size: USD 5.02 billion (2024) → USD 7.94 billion (2034)
• CAGR: 4.6 % (2025-2034)
• Top Segment: Shingles vaccines account for over 60 % of revenue
• Emerging Focus: Postherpetic neuralgia (PHN) management and novel antiviral research
• Regional Leaders: North America leads globally; Asia-Pacific expected to show fastest growth

Market Story
Herpes zoster, commonly known as shingles, is a reactivation of the varicella-zoster virus that causes painful rashes and neurological complications. With the global aging population rising, the disease burden has increased significantly - driving demand for preventive vaccination and antiviral treatments.

The introduction of recombinant zoster vaccines (RZV) such as Shingrix® by GSK plc has redefined market dynamics, offering over 90 % efficacy and longer-lasting protection than older live-attenuated vaccines.

Meanwhile, advancements in antiviral drugs, such as acyclovir, valacyclovir, and famciclovir, continue to support effective clinical management and postherpetic pain reduction.

Public health organizations and governments are expanding vaccination coverage, while pharmaceutical companies are developing next-generation vaccines and non-opioid pain management solutions for shingles-related neuropathy.

Segmentation Overview
By Treatment Type
• Antiviral Medications
o Acyclovir
o Valacyclovir
o Famciclovir
• Vaccines
o Recombinant Subunit Vaccines (Shingrix®, Others)
o Live-Attenuated Vaccines (Zostavax®)
• Pain Management Therapies
o Corticosteroids
o Anticonvulsants (Gabapentin, Pregabalin)
o Tricyclic Antidepressants
o Topical Analgesics
• Others (Supportive & Adjunctive Care)

By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By End User
• Hospitals
• Specialty Clinics
• Vaccination Centers

By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa

Explore Full Report here: https://exactitudeconsultancy.com/reports/49177/herpes-zoster-market

Recent Developments
• GSK plc reported expanding access to its leading Shingrix® vaccine, approved in more than 40 countries, including new market entries across Asia and Latin America.
• Merck & Co., Inc. continues to supply Zostavax® in select global regions, supporting public vaccination programs.
• Pfizer Inc. and BioNTech SE announced exploratory research into mRNA-based shingles vaccines under clinical development.
• Haleon (formerly GSK Consumer Healthcare) launched awareness initiatives to increase adult vaccination rates.
• Clinical trials investigating non-opioid pain relief for PHN continue across Europe and the U.S., addressing unmet patient needs.

Expert Quote
"Herpes zoster prevention and treatment are advancing rapidly due to innovations in vaccine technology and growing global immunization coverage.
With aging populations and improved healthcare access, the shingles market is set for long-term, steady growth,"
said Irfan Tamboli, Business Development Executive at Exactitude Consultancy.

Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=49177

Market Drivers
• Increasing global geriatric population and weakened immunity incidence
• Rising demand for recombinant zoster vaccines (RZV)
• Expansion of national immunization programs and public health campaigns
• Continuous R&D in antiviral therapy and postherpetic neuralgia management
• Growing pharmaceutical investment in rare and viral diseases

Forecast and Outlook
Between 2025 and 2034, the global herpes zoster market will evolve toward wider vaccination adoption and personalized care models.
Recombinant vaccines will dominate the prophylactic landscape, while mRNA-based and adjuvant-enhanced candidates will define the next generation of innovation.

Parallel growth will occur in the pain management segment, as biopharmaceutical firms introduce new non-opioid and neurostimulation-based therapies for PHN.
Emerging economies in Asia and Latin America are expected to witness rapid growth through government-funded adult immunization programs.

Regional Insights
• North America: Largest market; high awareness, vaccination rates, and strong pharma presence.
• Europe: Significant growth through healthcare reforms and geriatric vaccination initiatives.
• Asia-Pacific: Fastest-growing region due to increasing government vaccination drives in Japan, China, and India.
• Latin America: Expansion supported by WHO-backed immunization programs.
• Middle East & Africa: Gradual adoption as healthcare infrastructure and cold chain logistics improve.

Conclusion
The Global Herpes Zoster Market is advancing through a combination of scientific innovation, vaccine accessibility, and improved disease awareness.
As leading pharmaceutical companies invest in next-generation vaccines and pain management solutions, the next decade will mark a new era in shingles prevention and patient care.

This report is also available in the following languages : Japanese (帯状疱疹市場), Korean (대상포진 시장), Chinese (带状疱疹市场), French (Marché de l'herpès zoster), German (Herpes Zoster Markt), and Italian (Mercato dell'herpes zoster), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/49177/herpes-zoster-market#request-a-sample

Related Reports

Valganciclovir Hydrochloride Market
https://exactitudeconsultancy.com/reports/66324/valganciclovir-hydrochloride-market

Genital Herpes Market
https://exactitudeconsultancy.com/reports/71723/genital-herpes-market

Herpes Simplex Market
https://exactitudeconsultancy.com/reports/71741/herpes-simplex-market

Herpes Simplex Virus Treatment Market
https://exactitudeconsultancy.com/reports/75557/herpes-simplex-virus-treatment-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.